Schedule of Events | Appendix 1
Screening and Drug Administration

Phase of trial	Screening	Study Drug Administration									
Week		0	2	4	6	8	10	12	14		
Visit	-1	0	1	2	3	4	5	6	7	U[1]	TM/DV[2]
General Assessments											
Informed Consent	✔										
Eligibility criteria	✔										
Demographics (age, gender, ethnicity)	✔										
Medical history	✔										
Rheumatoid arthritis history	✔										
Comprehensive physical exam	✔	✔								✔	✔
Vital signs	✔	✔[3]	✔[3]	✔[3]		✔[3]		✔[3]		✔	✔
Randomization		✔									
Limited physical exam			✔	✔		✔		✔			
Adverse events		✔	✔	✔	✔	✔	✔	✔	✔	✔	✔
Concomitant medications	✔	✔	✔	✔	✔	✔	✔	✔	✔	✔	✔
Telephone assessment of changes since prior visit					✔		✔		✔		

1 Unscheduled Visit
2 Treatment Modification or Study Discontinuation visit. If treatment modification or intent to discontinue the study is identified during an in-person visit, convert that visit to a Treatment Modification Visit or Study Discontinuation visit. .If treatment modification or intent to discontinue the study is identified between in-person visits, then schedule the Treatment Modification or Study Discontinuation Visit for the next scheduled in-person visit
3 Vitals monitored per Protocol Section 6.1.1.2.4

Phase of trial	Screening	Study Drug Administration									
Week		0	2	4	6	8	10	12	14		
Visit	-1	0	1	2	3	4	5	6	7	U[1]	TM/DV[2]
Disease Specific Assessments											
Tender and swollen joint count[4]	✔	✔	✔	✔		✔		✔		✔	✔
Patient global health assessment (PaGH)	✔	✔	✔	✔		✔		✔		✔	✔
Health care provider global health assessment (PrGH)[4]	✔	✔	✔	✔		✔		✔		✔	✔
Pain assessment		✔								✔	✔
Health Assessment Questionnaire – Disability Index (HAQ-DI)		✔								✔	✔
PROMIS-29 Profile		✔								✔	✔
Study Drug Administration											
VIB4920 or VIB4920 placebo		✔	✔	✔		✔		✔			

4 Assessed by blinded evaluator

Phase of trial	Screening	Study Drug Administration									
Week		0	2	4	6	8	10	12	14		
Visit	-1	0	1	2	3	4	5	6	7	U[1]	TM/DV[2]
Clinical Laboratory Assessments (Central Lab)											
Hematology (CBC, differential, and platelet count)	✔	✔		✔		✔		✔		✔	✔
Serum chemistry (AST, ALT, bilirubin, alkaline phosphatase, albumin, creatinine)	✔	✔		✔		✔		✔		✔	✔
Inflammatory marker (C-reactive protein)	✔	✔	✔	✔		✔		✔		✔	✔
HIV (RNA or antibody)	✔										
Hepatitis B (core antibody, surface antigen)	✔										
Hepatitis C (RNA or antibody)	✔										
Tuberculosis Testing - QuantiFERON-TB Gold, QuantiFERON-TB Gold Plus, or T-SPOT.TB test[5]	✔										
Anti-phospholipid antibody testing (anti-cardiolipin IgG, IgM, and IgA; anti-beta-2-glycoprotein I IgG, IgM, and IgA; lupus anticoagulant)	✔										
SARS-CoV-2 PCR test	✔										
Serum pregnancy[6]	✔										
Rheumatoid Factor (RF)	✔									✔	✔
Anti-citrullinated peptide antibodies (ACPA)	✔									✔	✔
STAT urine pregnancy[6]		✔	✔	✔		✔		✔		✔	✔

5 For participants with indeterminate QuantiFERON-TB Gold, QuantiFERON-TB Gold Plus or T-SPOT.TB tests: 1) PPD skin test, if not performed within the past 3 months; 2) AP and lateral chest radiograph, if not performed within the past 3 months

6 For women with childbearing potential

Phase of trial	Screening	Study Drug Administration									
Week		0	2	4	6	8	10	12	14		
Visit	-1	0	1	2	3	4	5	6	7	U[1]	TM/DV[2]
Mechanistic Assessments											
Plasma PK pre-infusion assays[7]		✔	✔	✔		✔		✔			
Serum PK pre-infusion assays[7]		✔	✔	✔		✔		✔			
Plasma PK post-infusion[7]		✔						✔			
Plasma anti-drug antibody and sCD40L Assays[8]		✔	✔	✔		✔		✔			
PBMCs[8]		✔		✔				✔			✔
Serum[8]		✔		✔				✔			✔
Whole blood RNA[8]		✔		✔				✔			✔
Whole blood DNA[8]		✔		✔				✔			✔

7 Plasma and serum samples for PK collected pre-infusion and within 15 min +/- 5 min minutes post-infusion
8 Collected prior to infusion

Phase of Trial	Post-Administration Observation with Dense Sampling														
Week	16	17/18/19	20	21/22/23	24	25/26/27	28	29/30/31	32	33/34/35	36	37/38/39	40		
Visit	8	8.1/8.2/ 8.3	9	9.1/9.2/ 9.3	10	10.1/10.2/ 10.3	11	11.1/11.2/ 11.3	12	12.1/12.2/ 12.3	13	13.1/13.2/ 13.3	14	U[1]	TM/ DV[2]
General Assessments															
Comprehensive physical exam	✓												✓	✓	✓
Vital signs	✓		✓		✓		✓		✓		✓		✓	✓	✓
Limited physical exam			✓		✓		✓		✓		✓				
Adverse events	✓		✓		✓		✓		✓		✓		✓	✓	✓
Concomitant medications	✓		✓		✓		✓		✓		✓		✓	✓	✓
Disease Specific Assessments															
Tender and swollen joint count	✓		✓		✓		✓		✓		✓		✓	✓	✓
Patient global health assessment (PaGH)	✓		✓		✓		✓		✓		✓		✓	✓	✓
Health care provider global health assessment (PrGH)[3]	✓		✓		✓		✓		✓		✓		✓	✓	✓
Pain assessment	✓												✓	✓	✓
RAPID3 assessment (for dense sampling collection)	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓		✓
Health Assessment Questionnaire Disability Index (HAQ-DI)	✓												✓	✓	✓
PROMIS-29 Profile	✓												✓	✓	✓

1 Unscheduled visit
2 Treatment Modification or Study Discontinuation visit. If treatment modification or intent to discontinue the study is identified during an in person visit, convert that visit to a Treatment Modification Visit or Study Discontinuation visit. If treatment modification or intent to discontinue the study is identified between in-person visits, then schedule the Treatment Modification or Study Discontinuation Visit for the next scheduled in-person visit
3 Assessed by blinded evaluator

Phase of Trial	Post-Administration Observation with Dense Sampling														
Week	16	17/18/19	20	21/22/23	24	25/26/27	28	29/30/31	32	33/34/35	36	37/38/39	40		
Visit	8	8.1/8.2/ 8.3	9	9.1/9.2/ 9.3	10	10.1/10.2/ 10.3	11	11.1/11.2/ 11.3	12	12.1/12.2/ 12.3	13	13.1/13.2/ 13.3	14	U[1]	TM/ DV[2]
Clinical Laboratory Assessments (Central Lab)															
Hematology (CBC, differential, and platelet count)	✓				✓				✓				✓	✓	✓
Serum chemistry (AST, ALT, bilirubin, alkaline phosphatase, albumin, creatinine)	✓				✓				✓				✓	✓	✓
Inflammatory marker (C-reactive protein)	✓		✓		✓		✓		✓		✓		✓	✓	✓
Rheumatoid Factor (RF)	✓												✓	✓	✓
Anti-citrullinated peptide antibodies (ACPA)	✓												✓	✓	✓
Mechanistic Assessments															
Plasma PK Assay	✓		✓		✓		✓		✓		✓		✓		
Serum PK Assay	✓		✓		✓		✓		✓		✓		✓		
Plasma ADA and sCD40L Assays	✓		✓		✓		✓		✓		✓		✓		
PBMCs	✓				✓				✓				✓		✓
Serum	✓				✓				✓				✓		✓
Whole blood RNA	✓				✓				✓				✓		✓
Whole blood RNA-microcontainer (clinic collection)	✓														
Whole blood RNA-microcontainer (home collection for dense sampling collection)	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓		
Whole blood DNA	✓				✓				✓				✓		✓

Phase of trial	Post-Administration Observation								
Week	16	20	24	28	32	36	40		
Visit	8	9	10	11	12	13	14	U	TM/DV
General Assessments									
Comprehensive physical exam	✓						✓	✓	✓
Vital signs	✓	✓	✓	✓	✓	✓	✓	✓	✓
Limited physical exam		✓	✓	✓	✓	✓			
Adverse events	✓	✓	✓	✓	✓	✓	✓	✓	✓
Concomitant medications	✓	✓	✓	✓	✓	✓	✓	✓	✓
Disease Specific Assessments									
Tender and swollen joint count[1]	✓	✓	✓	✓	✓	✓	✓	✓	✓
Patient global health assessment (PaGH)	✓	✓	✓	✓	✓	✓	✓	✓	✓
Health care provider global health assessment (PrGH)[1]	✓	✓	✓	✓	✓	✓	✓	✓	✓
Pain assessment	✓						✓	✓	✓
Health Assessment Questionnaire – Disability Index (HAQ-DI)	✓						✓	✓	✓
PROMIS-29 Profile	✓						✓	✓	✓
Clinical Laboratory Assessments (Central Lab)									
Hematology (CBC, differential, and platelet count)	✓		✓		✓		✓	✓	✓
Serum chemistry (AST, ALT, bilirubin, alkaline phosphatase, albumin, creatinine)	✓		✓		✓		✓	✓	✓
Inflammatory marker (C-reactive protein)	✓	✓	✓	✓	✓	✓	✓	✓	✓
Rheumatoid Factor (RF)	✓						✓	✓	✓
Anti-citrullinated peptide antibodies (ACPA)	✓						✓	✓	✓
Mechanistic Assessments									
Plasma PK Assays	✓	✓	✓	✓	✓	✓	✓		
Serum PK Assays	✓	✓	✓	✓	✓	✓	✓		
Plasma ADA and sCD40L Assays	✓	✓	✓	✓	✓	✓	✓		
PBMCs	✓		✓		✓		✓		✓
Serum	✓		✓		✓		✓		✓
Whole blood RNA	✓		✓		✓		✓		✓
Whole blood DNA	✓		✓		✓		✓		✓

1 Assessed by blinded evaluator

Phase of trial	Alternate Monitoring									
Week of Study	2	4	8	12	16	24	32	40		
Visit	M1	M2	M3	M4	M5	M6	M7	M8	U[1]	DV[2]
General Assessments										
Vital signs	✔	✔	✔	✔	✔	✔	✔	✔	✔	✔
Limited physical exam	✔	✔	✔	✔	✔	✔	✔	✔	✔	✔
Adverse events[3]	✔	✔	✔	✔	✔	✔	✔	✔	✔	✔
Concomitant medications	✔	✔	✔	✔	✔	✔	✔	✔	✔	✔
Clinical Laboratory Assessments (Central Lab)										
Hematology (CBC, differential, and platelet count)		✔	✔	✔	✔			✔	✔	✔
Serum chemistry (AST, ALT, bilirubin, alkaline phosphatase, albumin, creatinine)		✔	✔	✔	✔			✔	✔	✔
Inflammatory marker (C-reactive protein)					✔			✔	✔	✔
Disease Specific Assessments										
Tender and swollen joint count[4]					✔			✔	✔	✔
Patient global health assessment (PaGH)					✔			✔	✔	✔
Health care provider global health assessment (PrGH)					✔			✔	✔	✔
Pain assessment					✔			✔	✔	✔

Additional assessments are permitted, if indicated for participant monitoring.

1 Unscheduled visit.
2 Study Discontinuation visit. If intent to discontinue the study is identified during an in-person visit, convert that visit to a Study Discontinuation visit. If intent to discontinue the study is identified between in-person visits, then schedule the Study Discontinuation Visit for the next scheduled in-person visit.
3 Adverse event monitoring will assess grade 2 or higher adverse events that receive medical attention and AESIs.
4 Assessed by blinded evaluator